Patents Issued in October 10, 2017
  • Patent number: 9782405
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 10, 2017
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • Patent number: 9782406
    Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: October 10, 2017
    Assignees: Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co., Ltd.
    Inventors: Zhengying Pan, Xitao Li
  • Patent number: 9782407
    Abstract: The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: October 10, 2017
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Anima Baruah, Dibyendu De, Ish Kumar Khanna, Sivaram Pillarisetti, Santanu Maitra, Christopher W. Alexander, Jennepalli Sreenu, Indu Dager, Shanavas Alikunju
  • Patent number: 9782408
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: October 10, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Patent number: 9782409
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 10, 2017
    Assignee: The University of Manchester
    Inventors: Ian Hampson, Lynne Hampson
  • Patent number: 9782410
    Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 10, 2017
    Assignee: REXAHN PHARMACEUTICALS, INC.
    Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
  • Patent number: 9782411
    Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: October 10, 2017
    Assignee: SANOFI
    Inventors: Véronique Briand, Sabine Gratzer, Thomas Huebschle, Philip Janiak, Dieter Kadereit, Ashfaq Parkar, Bruno Poirier, Matthias Schaefer, Paulus Wohlfart
  • Patent number: 9782412
    Abstract: Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R1 to R3, W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 10, 2017
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Fumihito Hosoi, Yoshinori Nakachi, Daisuke Kajiwara
  • Patent number: 9782413
    Abstract: The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid and its use for the treatment of essential thrombocythemia.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 10, 2017
    Assignee: AOP ORPHAN PHARMACEUTICALS AC
    Inventors: Rudolf Widmann, Georg Strieder
  • Patent number: 9782414
    Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: October 10, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
  • Patent number: 9782415
    Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: October 10, 2017
    Assignee: Array BioPharma, Inc.
    Inventors: Shelley Allen, Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Lily Huang, Yutong Jiang, Timothy Kercher, Jeongbeob Seo
  • Patent number: 9782416
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: October 10, 2017
    Assignee: Essentialis, Inc.
    Inventor: Neil Madison Cowen
  • Patent number: 9782417
    Abstract: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: October 10, 2017
    Assignee: Presidents and Fellows of Harvard College
    Inventors: Lee L. Rubin, Amanda Gee, Amy J. Wagers
  • Patent number: 9782418
    Abstract: The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: October 10, 2017
    Assignee: Celestra Life Science LLC
    Inventors: Allen J. Lee, Jason J. Lee, David M. Lu, Ruey-Min Lee
  • Patent number: 9782419
    Abstract: Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 10, 2017
    Assignee: Agile Therapeutics, Inc.
    Inventors: Thomas M. Rossi, Marie Foegh, Agis Kydonieus
  • Patent number: 9782420
    Abstract: The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: October 10, 2017
    Assignee: Kyoto University
    Inventors: Akira Kakizuka, Hanako Ikeda, Nagahisa Yoshimura, Yuki Muraoka
  • Patent number: 9782421
    Abstract: Complexes of neridronic acid, in an acid or a salt form, with amino acids, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: October 10, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9782422
    Abstract: We describe a composition comprising a non-digestible oligosaccharide for the treatment, prevention or alleviation of a trichothecene mycotoxin exposure associated condition. The non-digestible oligosaccharide may comprise a galactooligosaccharide and/or fructooligosaccharide. The non-digestible oligosaccharide may comprise a short chain galacto-oligosaccharide (scGOS) and/or short chain fructooligosaccharide (scFOS). The trichothecene mycotoxin exposure associated condition may be associated with exposure to deoxynivalenol.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: October 10, 2017
    Assignee: N.V. Nutricia
    Inventors: Johan Garssen, Hermiena Christina Schoterman, Johanna Fink-Gremmels, Saskia Braber
  • Patent number: 9782423
    Abstract: The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: October 10, 2017
    Assignee: Novabiotics Limited
    Inventors: Deborah O'Neil, Cedric Charrier
  • Patent number: 9782424
    Abstract: The present invention includes a composition comprising an effective amount of an avermectin compound, and an effective amount of an imidazole antifungal compound, and/or an effective amount of non-steroidal anti-inflammatory drug (NSAID) or suitable pharmaceutically acceptable salts thereof, for use in the inhibition of tumor growth and treating urothelial, colorectal, prostate and/or breast cancers. Furthermore, the invention includes a method of inhibiting tumor growth and treating said cancers comprising administering to a subject in need thereof an effective amount of said composition.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 10, 2017
    Assignee: ECTIN RESEARCH AB
    Inventors: Christer Edlund, Peter Falk, Marie-Lois Ivarsson
  • Patent number: 9782425
    Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: October 10, 2017
    Assignee: Galderma S.A.
    Inventors: Jean Jacovella, Jean-Paul Chappuis, Alexandre Kaoukhov, Michael Graeber, Laurence Salin, Michel Poncet, Philippe Briantais
  • Patent number: 9782426
    Abstract: This invention relates to a topical composition for prevention and treatment of viral infections.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 10, 2017
    Assignee: Cutanea Life Sciences, Inc.
    Inventors: Linda M. Mahoney, Anne T. Moore, Gary Lee Feiss, Danielle N. Ringhoff
  • Patent number: 9782427
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor having the following formula (I): and an effective amount of a cytidine analog, such as 5-azacytidine, to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Heather Raymon
  • Patent number: 9782428
    Abstract: Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: October 10, 2017
    Assignee: Northeastern University
    Inventors: Michail V. Sitkovsky, Robert Koehler Abbott, Stephen Matthew Hatfield
  • Patent number: 9782429
    Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 10, 2017
    Assignee: GENTIUM S.R.L.
    Inventors: Laura Ferro, Roberto Porta, Massimo Iacobelli, Alessandro Massimo Gianni, Carmelo Carlo Stella
  • Patent number: 9782430
    Abstract: A method for forming an embolism within a blood vessel is disclosed. The method includes including: implanting an oxidized cellulose embolization solution into a lumen of a blood vessel to form an embolism within the lumen. The oxidized cellulose is present in an amount from about 10 % by weight to 20 % by weight of the oxidized cellulose embolization solution. The method also includes adjusting recanalization time of the embolism, which may be adjusted by tailoring a degradation rate of the oxidized cellulose.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: October 10, 2017
    Assignee: Covidien LP
    Inventors: Rachit Ohri, Phillip D. Blaskovich
  • Patent number: 9782431
    Abstract: The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides reduce body weight and fat accumulation in laboratory animals, and can therefore be used to prevent and treat obesity.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 10, 2017
    Assignee: Chang Gung Biotechnology Corp.
    Inventors: Yun-Fei Ko, Jan Martel, Jian-Ching Liau, I-Te Chang, Chien-Sheng Lee, Wei-Chang Wang, Chen-Yaw Chiu, Chih-Jung Chang, Chuan-Sheng Lin, Tsung-Ru Wu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, Ding-E Young
  • Patent number: 9782432
    Abstract: Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 1 or more. Other embodiments of the invention provide a therapeutic method for treating a wound in an animal comprising administering to an animal in need of such therapy, an effective amount of a copolymer as described herein.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 10, 2017
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Kathryn E. Uhrich, Sabrina S. Snyder
  • Patent number: 9782433
    Abstract: In one or more embodiments, the present invention relates to a substantially homogeneous miscible liquid adhesive composition comprising a relatively high number average molecular weight (Mn=6,000-10,000 g/mole) cyanoacrylate tri-telechelic star polymer having polyisobutylene chains terminated with cyanoacrylate groups (High-Ø(PIB-CA)3); 2-octyl cyanoacrylate (Oct-CA); and a relatively low molecular weight (Mn=1,000-4,000 g/mole) cyanoacrylate tri-telechelic star polymer having polyisobutylene chains terminated with cyanoacrylate groups (Low-Ø(PIB-CA)3). The Low-Ø(PIB-CA)3 compatibilizes the High-Ø(PIB-CA)3 and Oct-CA removing the need for a solvent. When the substantially homogeneous miscible liquid adhesive compositions of various embodiments are reacted with a nucleophile, such as water or an initiator, they form a polymer co-network suitable for any of a number of biomedical applications, from wound closure and healing of skin tissue, to sealant for surgical cuts.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: October 10, 2017
    Assignee: The University of Akron
    Inventors: Joseph Kennedy, Istvan Szanka, Amalia Szanka
  • Patent number: 9782434
    Abstract: Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: October 10, 2017
    Assignee: Sonoma Pharmaceuticals, Inc.
    Inventors: Hojabr Alimi, Andrés Gutiérrez
  • Patent number: 9782435
    Abstract: Composites and methods of producing a mouldable bone substitute are described. A scaffold for bone growth comprises nanocrystalline hydroxyapatite (HA), a bioresorbable plasticizer, and a biodegradable polymer. Plasticizers of the invention include oleic acid, tocopherol, eugenol, 1,2,3-triacetoxypropane, monoolein, and octyl-beta-D-glucopyranoside. Polymers of the invention include poly(caprolactone), poly(D,L-Lactic acid), and poly(glycolide-co lactide). Methods of regulating porosity, hardening speed, and shapeability are also described. Composites and methods are described using nanocrystalline HA produced with and without amino acids. The scaffold for bone growth described herein displays increased strength and shapeability.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: October 10, 2017
    Assignee: Promimic AB
    Inventors: Per Kjellin, Paul Handa
  • Patent number: 9782436
    Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: October 10, 2017
    Assignee: LifeCell Corporation
    Inventor: Wenquan Sun
  • Patent number: 9782437
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 10, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Fyodor Urnov
  • Patent number: 9782438
    Abstract: Disclosed are a method of promoting hair growth or preventing hair loss in a mammal. In one aspect, the method includes administering interdermally or subcutaneously an agent containing an active ingredient comprising bFGF and a pharmaceutically acceptable substance, wherein bFGF is administered in a dose of 1 ?g to 100 ?g per 1 cm2 of the target area of hair growth treatment or hair loss prevention and a composition for use in the method.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: October 10, 2017
    Assignee: H CELL, INC.
    Inventor: Jaehyun Lim
  • Patent number: 9782439
    Abstract: Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 ?m) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: October 10, 2017
    Assignee: JAPAN HEALTH SCIENCES FOUNDATION
    Inventors: Noritoshi Nagaya, Hidezo Mori, Yoshinori Miyahara
  • Patent number: 9782440
    Abstract: One aspect of the present disclosure can include a therapeutic composition useful for treatment of a genitourinary disorder. The composition can be derived from a culture media having been in contact with a population of bone marrow-derived mesenchymal stem cells for a sufficient time period necessary to endow therapeutic activity in the culture media. The therapeutic property endowed to the culture media is the ability to promote structural and functional recovery of a dysfunctional organ or biological tissue associated with the genitourinary disorder.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: October 10, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Margot S. Damaser, Charuspong Dissaranan, Howard B. Goldman, Matthew Kiedrowski, Marc S. Penn
  • Patent number: 9782441
    Abstract: Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow stromal cells expanded in culture, adipose-tissue derived non-adherent stromal cells, or the culture supernatant thereof.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: October 10, 2017
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Chandan Guha, Subhrajit Saha, Alan A. Alfieri, Payel Bhanja
  • Patent number: 9782442
    Abstract: Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: October 10, 2017
    Assignee: Versitech Limited
    Inventors: Ho Cheung Shum, Yang Song
  • Patent number: 9782443
    Abstract: The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F12 medium; N2 supplement; retinoic acid; and BMP-4.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: October 10, 2017
    Assignee: Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences
    Inventors: Duanqing Pei, Jinglei Cai, Pengfei Liu, Shubin Chen, Yanmei Zhang
  • Patent number: 9782444
    Abstract: The present invention relates to a method for fermenting fish skin by using Aspergillus. Also provided is a use of the fermentation liquid obtained by fermenting fish skin with Aspergillus obtained from the method in inhibiting the activity of tyrosinase, inhibiting the activity of angiotensin-converting enzyme and/or improving the survival of fibroblasts.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: October 10, 2017
    Assignee: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE
    Inventors: Shu-Chen Huang, Pei-Jou Liu, Chiao-Ming Liao, Hing-Yuen Chan
  • Patent number: 9782445
    Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: October 10, 2017
    Assignee: Rebiotix, Inc.
    Inventors: Lee A. Jones, Courtney R. Jones, Mary Kay Sobcinski
  • Patent number: 9782446
    Abstract: Disclosed are novel Lactobacillus plantarum strains as well as a composition containing the novel Lactobacillus plantarum strains or a culture thereof.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: October 10, 2017
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Il Young Kwack, Se Jin You, Tae-Hun Park, Bum Jin Lee, Kye Ho Shin, Jin Oh Chung, Jun Cheol Cho
  • Patent number: 9782447
    Abstract: The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides can reduce liver size, weight and the number and size of liver lipid vacuoles, as well as serum triglycerides and serum aspartate aminotransferase levels in humans and animals. The prepared polysaccharides can therefore be used to prevent and treat fatty liver disease.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 10, 2017
    Assignee: Chang Gung Biotechnology Corp.
    Inventors: Yun-Fei Ko, Jan Martel, Jian-Ching Liau, I-Te Chang, Chien-Sheng Lee, Wei-Chang Wang, Chen-Yaw Chiu, Chih-Jung Chang, Chuan-Sheng Lin, Tsung-Ru Wu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, Ding-E Young
  • Patent number: 9782448
    Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: October 10, 2017
    Assignee: ELC Management LLC
    Inventors: Donald F. Collins, Daniel H. Maes, Neelam Muizzuddin
  • Patent number: 9782449
    Abstract: A method for the treatment of addiction to tobacco includes the stages of i) interviewing and training of a tobacco user (patient) and an accompanying person (ii) undergoing a Domiciliary Intensive Detoxification Program, including breathing and corporal exercises, directed balneotherapy, dietary measures including the intake of selected groups of foods and aloe vera gel, hygienic and oral rehabilitation measures and (iii) adhering to a maintenance program.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: October 10, 2017
    Assignee: AMERICAN LIFE NATURALLY
    Inventor: Pabla Beatriz Rojas de Naguila
  • Patent number: 9782450
    Abstract: Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: October 10, 2017
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Douglas Kalman, Beena Bhat, Priti Vaidyanathan, Sarang Bani, Anjali Pandey, Suresh Karri
  • Patent number: 9782451
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: October 10, 2017
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • Patent number: 9782452
    Abstract: This disclosure demonstrates that blockade of TGF? signaling after a hematopoietic stress (e.g., chemotherapy, transplantation, and infection) accelerates hematopoietic reconstitution and delays the return of cycling hematopoietic stem and progenitor cells (HSPCs) to quiescence. TGF? blockade in these settings promotes multilineage hematopoietic regeneration by prolonging HSPC cycling and by promoting HSC self-renewal, and is useful for treating hematologic deficiencies caused various hematopoietic stresses.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: October 10, 2017
    Assignee: Cornell University
    Inventors: Joseph Scandura, Fabienne Brenet
  • Patent number: 9782453
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: October 10, 2017
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Patent number: 9782454
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: October 10, 2017
    Assignee: LONGEVITY BIOTECH, INC.
    Inventors: Scott J. Shandler, Samuel H. Gellman